I 
116TH CONGRESS 
1ST SESSION H. R. 4322 
To promote cannabis research, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
SEPTEMBER 12, 2019 
Ms. SHALALA (for herself, Mr. GAETZ, and Ms. LEE of California) introduced 
the following bill; which was referred to the Committee on Energy and 
Commerce, and in addition to the Committee on the Judiciary, for a pe-
riod to be subsequently determined by the Speaker, in each case for con-
sideration of such provisions as fall within the jurisdiction of the com-
mittee concerned 
A BILL 
To promote cannabis research, and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Expanding Cannabis 
Research and Information Act’’. 
SEC. 2. CANNABIS RESEARCH AT THE DEPARTMENT OF 
HEALTH AND HUMAN SERVICES. 
(a) NATIONAL CANNABIS RESEARCH AGENDA.—Part 
B of title IV of the Public Health Service Act (42 U.S.C. 
VerDate Sep 11 2014 
23:16 Sep 13, 2019
Jkt 089200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H4322.IH
H4322
kjohnson on DSK79L0C42 with BILLS
284 et seq.) is amended by adding at the end the fol-
lowing: 
‘‘SEC. 409K. NATIONAL CANNABIS RESEARCH AGENDA. 
‘‘Not later than 1 year after the date of enactment 
of the Expanding Cannabis Research and Information 
Act, the Director of NIH, in collaboration with the Direc-
tor of the Centers for Disease Control and Prevention and 
the Assistant Secretary for Mental Health and Substance 
Use, shall develop a national cannabis research agenda 
that addresses key questions and gaps in evidence, includ-
ing with respect to each of the following: 
‘‘(1) The efficacy of cannabis in providing 
therapeutic benefits for certain priority diseases or 
conditions, which may include epilepsy, multiple scle-
rosis-related spasticity, chemotherapy-induced pain 
and discomfort, using cannabis as an alternative to 
opioid analgesics for acute or chronic pain, sleep 
apnea, Tourette syndrome, anxiety, post-traumatic 
stress disorder, and any other disease or condition 
determined to be appropriate and of importance by 
the Director. 
‘‘(2) The effect of cannabis on at-risk popu-
lations, including children, older individuals, and 
pregnant or breast-feeding women. 
VerDate Sep 11 2014 
23:16 Sep 13, 2019
Jkt 089200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H4322.IH
H4322
kjohnson on DSK79L0C42 with BILLS
‘‘(3) The long-term effects of cannabis use, in-
cluding dose-response relationship and the connec-
tion between cannabis use and behavioral health. 
‘‘(4) The clinically appropriate modes of deliv-
ery of cannabis. 
‘‘(5) Public safety considerations related to can-
nabis, including— 
‘‘(A) variation in the potency of cannabis 
products; 
‘‘(B) youth access to and use of cannabis, 
including marketing, packaging, edible formula-
tions, and flavor options that target youth; 
‘‘(C) risk factors for cannabis misuse; 
‘‘(D) impaired driving related to cannabis 
use; and 
‘‘(E) accidental ingestion of cannabis.’’. 
(b) SURVEILLANCE ACTIVITIES.—Part A of title III 
of the Public Health Service Act (42 U.S.C. 241 et seq.) 
is amended by adding at the end the following: 
‘‘SEC. 310B. SURVEILLANCE ACTIVITIES ON CANNABIS USE. 
‘‘(a) IN GENERAL.—The Secretary, acting through 
the Director of the Centers for Disease Control and Pre-
vention, in collaboration with the Assistant Secretary for 
Mental Health and Substance Use, the Administrator of 
the Centers for Medicare & Medicaid Services, and the Di-
VerDate Sep 11 2014 
23:16 Sep 13, 2019
Jkt 089200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H4322.IH
H4322
kjohnson on DSK79L0C42 with BILLS